• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Gilead Sciences, Mobiquity each open new London headquarters

Gilead Sciences, Mobiquity each open new London headquarters

February 11, 2015
CenterWatch Staff

Gilead Sciences, a U.S.-based biotechnology company, is deepening its U.K. presence with a new commercial headquarters in the heart of London from which to grow the company's portfolio, which includes treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular diseases and cancer. The company's presence in London will foster closer partnerships with clinicians, patient groups and National Health Service and government organizations, as Gilead continues its efforts to broaden access to innovative medicines.

The new London headquarters and expansions of its international operations in Uxbridge and U.K. R&D headquarters in Cambridge ​represent an increased investment in the U.K. of $19.6 million and a doubling of Gilead's U.K. workforce from 2013 to 2015, with 400 out of 600 U.K. employees based in London.

Gilead is joined in London by Boston-based Mobiquity, a mobile engagement company with clients including Pfizer, Merck, AbbVie and Weight Watchers. Attracted by London's strengths in digital health, Mobiquity is basing its $20 million European headquarters in the city. Early projects will include working with Pfizer to develop digital technologies that enable people to manage their own health, a key focus for the U.K.'s National Health Service. 

The new investment follows recent announcements by healthcare companies including Merck and Pfizer that they will establish or expand operations in London.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing